ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Tuesday, November 14, 2023

11:00AM-12:30PM: Abstract Number: 2425

Pregnancy Outcomes Among Patients with Vasculitis Using Administrative Claims Data

Plenary III

11:00AM-12:30PM: Abstract Number: 2429

Romosozumab versus Denosumab in High-risk Patients Treated with Glucocorticoids: Interim 12-month Results from a Pilot Randomized Controlled Trial

Plenary III

11:00AM-12:30PM: Abstract Number: 2426

The Role of β-catenin in Synovial Lining Fibroblast Differentiation

Plenary III

11:00AM-12:30PM: Abstract Number: 2430

Time-Dependent Evaluation of Weighted Cumulative Glucocorticoid Exposure and Major Adverse Cardiovascular Events in a Cohort of Veterans with Rheumatoid Arthritis

Plenary III

11:00AM-12:30PM: Abstract Number: 2428

Unclosing Premature Mortality Gap Among Gout Patients in the US General Population, Independent of Serum Urate and Atherosclerotic Cardiovascular Risk Factors

Plenary III

2:00PM-3:30PM: Abstract Number: 2473

A Consensus Based Algorithm to Screen for Lung Disease in Children with Systemic Juvenile Idiopathic Arthritis

Abstracts: Pediatric Rheumatology – Clinical III: Potpourri

2:00PM-3:30PM: Abstract Number: 2434

Acetylated Bacterial Proteins as Potent Antigens Inducing an Anti-modified Protein Antibody Response

Abstracts: RA – Etiology & Pathogenesis

2:00PM-3:30PM: Abstract Number: 2455

Addressing Native American Health Disparities in Rheumatoid Arthritis by Training Primary Care Providers: Expanding the Reach of the RAE Initiative

Abstracts: Healthcare Disparities in Rheumatology

2:00PM-3:30PM: Abstract Number: 2457

Ageism in Rheumatology: The Health Care Professional’s Perspective

Abstracts: Healthcare Disparities in Rheumatology

2:00PM-3:30PM: Abstract Number: 2491

Alignment Between the Novel 2022 ACR/EULAR Classification Criteria for ANCA-associated Vasculitis (AAV), Clinical Diagnosis and Organ Manifestations in a European AAV Cohort

Abstracts: Vasculitis – ANCA-Associated II

2:00PM-3:30PM: Abstract Number: 2477

Anifrolumab Normalizes the Type I Interferon Signature in a Cohort of Patients with Type I Interferonopathies

Abstracts: Pediatric Rheumatology – Clinical III: Potpourri

2:00PM-3:30PM: Abstract Number: 2452

Assessment of Association Between Hydroxychloroquine Use and Toxic Retinopathy, Overall and by Indication, in a Large Cohort of Rheumatology Patients Within the US Department of Defense Military Healthcare System

Abstracts: Epidemiology & Public Health II

2:00PM-3:30PM: Abstract Number: 2468

Association Between Gut Microbiome-related Metabolites and Symptomatic Hand Osteoarthritis in Two Independent Cohorts

Abstracts: Osteoarthritis II: Novel Insights from Observational Studies

2:00PM-3:30PM: Abstract Number: 2469

Associations Between Body Composition Measurements of Obesity and the Radiographic Progression of Hand Osteoarthritis: Data from the Dong-gu Study

Abstracts: Osteoarthritis II: Novel Insights from Observational Studies

2:00PM-3:30PM: Abstract Number: 2464

B Cells in Anti-tRNA Synthetase Syndrome Patients Show an Activated, Interferon Responsive Signature

Abstracts: Muscle Biology, Myositis & Myopathies – Basic & Clinical Science I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].